ANEBULO PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Increase (Decrease) in Prepaid Expense of -$86.03 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was $4.64K, a 91.30% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was -$90.67K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-06-30 was -$266.60K, a 240.23% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-03-31 was $161.77K, a 211.48% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2025 was -$152.35K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2024 was -$8.96K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2023 was -$608.21K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2022 was -$636.89K, a 138.19% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$86.03K 10-Q · filed 2026-02-12 | -$352.62K derived: sum of 3 quarters · filed 2026-02-12 | -$190.85K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-09-30 | -$90.67K 10-Q · filed 2025-11-13 | -$357.26K derived: sum of 2 quarters · filed 2025-11-13 | -$195.50K derived: sum of 3 quarters · filed 2025-11-13 | -$142.17K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-06-30 | -$266.60K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$104.83K derived: sum of 2 quarters · filed 2025-09-29 | -$51.50K derived: sum of 3 quarters · filed 2026-02-12 | -$152.35K 10-K · filed 2025-09-29 |
| 2025-03-31 | $161.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $215.09K derived: sum of 2 quarters · filed 2026-02-12 | $114.24K 10-Q · filed 2025-05-13 | $304.36K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $53.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$47.52K 10-Q · filed 2026-02-12 | $142.59K derived: sum of 3 quarters · filed 2026-02-12 | $194.53K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | -$100.85K 10-Q · filed 2025-11-13 | $89.26K derived: sum of 2 quarters · filed 2025-11-13 | $141.20K derived: sum of 3 quarters · filed 2025-11-13 | -$214.37K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $190.11K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $242.05K derived: sum of 2 quarters · filed 2025-09-29 | -$113.52K derived: sum of 3 quarters · filed 2025-09-29 | -$8.96K 10-K · filed 2025-09-29 |
| 2024-03-31 | $51.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$303.63K derived: sum of 2 quarters · filed 2025-05-13 | -$199.07K 10-Q · filed 2025-05-13 | -$44.13K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$355.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$251.01K 10-Q · filed 2025-02-14 | -$96.06K derived: sum of 3 quarters · filed 2025-02-14 | -$361.17K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $104.56K 10-Q · filed 2024-11-13 | $259.50K derived: sum of 2 quarters · filed 2024-11-13 | -$5.60K derived: sum of 3 quarters · filed 2024-11-13 | -$74.36K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $154.95K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | -$110.16K derived: sum of 2 quarters · filed 2024-09-25 | -$178.92K derived: sum of 3 quarters · filed 2024-09-25 | -$608.21K 10-K · filed 2024-09-25 |
| 2023-03-31 | -$265.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | -$333.87K derived: sum of 2 quarters · filed 2024-05-15 | -$763.16K 10-Q · filed 2024-05-15 | -$432.94K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$68.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$498.05K 10-Q · filed 2024-02-13 | -$167.83K derived: sum of 3 quarters · filed 2024-02-13 | -$421.98K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$429.29K 10-Q · filed 2023-11-14 | -$99.07K derived: sum of 2 quarters · filed 2023-11-14 | -$353.21K derived: sum of 3 quarters · filed 2023-11-14 | -$690.93K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $330.22K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | $76.08K derived: sum of 2 quarters · filed 2023-09-22 | -$261.64K derived: sum of 3 quarters · filed 2023-09-22 | -$636.89K 10-K · filed 2023-09-22 |
| 2022-03-31 | -$254.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$591.86K derived: sum of 2 quarters · filed 2023-05-11 | -$967.11K 10-Q · filed 2023-05-11 | |
| 2021-12-31 | -$337.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-10 | -$712.97K 10-Q · filed 2023-02-10 | ||
| 2021-09-30 | -$375.25K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $1.67M 10-K · filed 2022-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |